Conquering the cytokine storm in COVID‐19‐induced ARDS using placenta‐derived decidua stromal cells
| Autor: | Maryam Salimi, Mohammad Mahdi Majidi, Elham Roshandel, Sarvenaz Samadi Kochaksaraei, Abbas Hajifathali, Farshid Alaeddini, Sepide Kazemi, Nasser Aghdami, Behnam Sadeghi, Olle Ringdén, Ali Pirsalehi, Hoda Sadrosadat, Ghazaleh Sankanian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty ARDS Stromal cell Adolescent Cell Transplantation medicine.medical_treatment Placenta Gastroenterology intensive care unit survival law.invention law COVID‐19 Pregnancy Internal medicine medicine Humans Myocardial infarction Aged Respiratory Distress Syndrome business.industry Decidua COVID-19 Cell Biology Oxygenation Original Articles Length of Stay Middle Aged medicine.disease Intensive care unit COVID-19 Drug Treatment medicine.anatomical_structure Cytokine Treatment Outcome decidua stromal cells cytokine storm Molecular Medicine Cytokines Original Article Female Stromal Cells Cytokine storm business Cytokine Release Syndrome |
| Zdroj: | Journal of Cellular and Molecular Medicine |
| ISSN: | 1582-4934 1582-1838 |
| Popis: | Acute respiratory distress syndrome (ARDS) is the most common cause of death in COVID‐19 patients. The cytokine storm is the main driver of the severity and magnitude of ARDS. Placenta‐derived decidua stromal cells (DSCs) have a stronger immunosuppressive effect than other sources of mesenchymal stromal cells. Safety and efficacy study included 10 patients with a median age of 50 (range 14–68) years with COVID‐19‐induced ARDS. DSCs were administered 1–2 times at a dose of 1 × 106/kg. End points were safety and efficacy by survival, oxygenation and effects on levels of cytokines. Oxygenation levels increased from a median of 80.5% (range 69–88) to 95% (range 78–99) (p = 0.012), and pulmonary infiltrates disappeared in all patients. Levels of IL‐6 decreased from a median of 69.3 (range 35.0–253.4) to 11 (range 4.0–38.3) pg/ml (p = 0.018), and CRP decreased from 69 (range 5–169) to 6 (range 2–31) mg/ml (p = 0.028). Two patients died, one of a myocardial infarction and the other of multiple organ failure, diagnosed before the DSC therapy. The other patients recovered and left the intensive care unit (ICU) within a median of 6 (range 3–12) days. DSC therapy is safe and capable of improving oxygenation, decreasing inflammatory cytokine level and clearing pulmonary infiltrates in patients with COVID‐19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text